Loading clinical trials...
Loading clinical trials...
Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.
Conditions
Interventions
PDR001
LAG525
Locations
20
United States
California Pacific Medical Center Drug Shipment (2)
San Francisco, California, United States
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida, United States
University Cancer and Blood Center, LLC
Athens, Georgia, United States
Northwestern University Medical School
Chicago, Illinois, United States
University of Illinois Cancer Center at Chicago SC
Chicago, Illinois, United States
Illinois Cancer Care P.C. Jesse Brown VA
Peoria, Illinois, United States
Start Date
January 24, 2018
Primary Completion Date
February 21, 2019
Completion Date
September 17, 2020
Last Updated
May 27, 2022
NCT07177937
NCT06043817
NCT05671510
NCT06340711
NCT06257264
NCT07144280
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions